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Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative method for blood cancers and other
blood disorders, but is limited by the development of graft-versus-host disease (GVHD). GVHD results in
inflammatory damage to the host liver, gastrointestinal tract and skin, resulting in high rates of morbidity and
mortality in HSCT recipients. Activation of the A2A receptor has been previously demonstrated to reduce
disease in allogeneic mouse models of GVHD. This study aimed to investigate the effect of A2A activation on
disease development in a humanised mouse model of GVHD. Immunodeficient non-obese diabetic-severe
combined immunodeficiency-interleukin (IL)-2 receptor γnull (NSG) mice injected with human (h)
peripheral blood mononuclear cells (hPBMCs), were treated with either the A2A agonist CGS 21680 or
control vehicle. Contrary to the beneficial effect of A2A activation in allogeneic mouse models, CGS 21680
increased weight loss, and failed to reduce the clinical score or increase survival in this humanised mouse
model of GVHD. Moreover, CGS 21680 reduced T regulatory cells and increased serum human IL-6
concentrations. Conversely, CGS 21680 reduced serum human tumour necrosis factor (TNF)-α
concentrations and leukocyte infiltration into the liver, indicating that A2A activation can, in part, reduce
molecular and histological GVHD in this model. Notably, CGS 21680 also prevented healthy weight gain in
NSG mice not engrafted with hPBMCs suggesting that this compound may be suppressing appetite or
metabolism. Therefore, the potential benefits of A2A activation in reducing GVHD in HSCT recipients may
be limited and confounded by adverse impacts on weight, decreased T regulatory cell frequency and increased
IL-6 production.
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ABSTRACT:  23 
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative method for blood 24 
cancers and other blood disorders, but is limited by the development of graft-versus-host 25 
disease (GVHD). GVHD results in inflammatory damage to the host liver, gastrointestinal 26 
tract and skin, resulting in high rates of morbidity and mortality in HSCT recipients. 27 
Activation of the A2A receptor has been previously demonstrated to reduce disease in 28 
allogeneic mouse models of GVHD. This study aimed to investigate the effect of A2A 29 
activation on disease development in a humanised mouse model of GVHD. Immunodeficient 30 
non-obese diabetic-severe combined immunodeficiency-interleukin (IL)-2 receptor γnull 31 
(NSG) mice injected with human (h) peripheral blood mononuclear cells (hPBMCs), were 32 
treated with either the A2A agonist CGS 21680 or vehicle control. Contrary to the beneficial 33 
effect of A2A activation in allogeneic mouse models, CGS 21680 increased weight loss, and 34 
failed to reduce the clinical score or increase survival in this humanised mouse model of 35 
GVHD. Moreover, CGS 21680 reduced T regulatory cells and increased serum human IL-6 36 
concentrations. Conversely, CGS 21680 reduced serum human tumour necrosis factor 37 
(TNF)-α concentrations and leukocyte infiltration into the liver, indicating that A2A activation 38 
can, in part, reduce molecular and histological GVHD in this model. Notably, CGS 21680 39 
also prevented healthy weight gain in NSG mice not engrafted with hPBMCs suggesting that 40 
this compound may be suppressing appetite or metabolism. Therefore, the potential benefits 41 
of A2A activation in reducing GVHD in HSCT recipients may be limited and confounded by 42 
adverse impacts on weight, decreased T regulatory cell frequency and increased IL-6 43 
production. 44 
  45 
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INTRODUCTION 46 
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative method for 47 
numerous haematological malignancies and other blood disorders; however, HSCT is limited 48 
by the development of graft-versus-host disease (GVHD) [1]. GVHD develops in up to 60% 49 
of HSCT recipients [2], due to donor T cells recognising ‘foreign’ host cells [3]. GVHD 50 
when damage caused by the conditioning regime or the underlying disease promotes the 51 
release of inflammatory cytokines such as tumour necrosis factor (TNF)-α and interleukin 52 
(IL)-6. Subsequently, activation of T cells by dendritic cells (DCs) results in the further 53 
release of TNF-α as well as interferon (IFN)-γ, IL-2 and IL-6 to promote inflammation, and 54 
subsequent activation of CD8+ T cells to exacerbate this inflammation. Conversely, T 55 
regulatory (Treg) cells and invariant natural killer T (iNKT) cells can reduce pro-56 
inflammatory effects in GVHD to limit disease development or progression [4].   57 
Adenosine receptors (A1, A2A, A2B and A3) are cell-surface G-protein coupled receptors 58 
activated by extracellular adenosine [5]. Extracellular adenosine is often produced as a result 59 
of ATP hydrolysis mediated by the sequential action of ecto-nucleoside triphosphate 60 
diphosphohydrolase-1 (CD39), and ecto-5’-nucleotidase (CD73) [6,7]. The A2A receptor is 61 
expressed on numerous immune cell subsets including DCs and T cells [8]. Notably,  62 
CD39/CD73-mediated production of adenosine and subsequent activation of A2A is an 63 
important anti-inflammatory mechanism [9]. In allogeneic mouse models of transplantation, 64 
adenosine production by the CD39/CD73 pathway and subsequent activation of adenosine 65 
receptors prevents tissue damage and reduces graft rejection [10]. In allogeneic mouse 66 
models of GVHD, genetic deficiency or pharmacological blockade of CD73 with αβ-67 
methylene ADP (APCP) [11], which results in reduced extracellular adenosine, worsens 68 
disease. Similarly, genetic deficiency [11,12] or pharmacological blockade of A2A with 69 
SCH58261 [12] also worsens GVHD severity in these models. Conversely, activation of A2A 70 
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with ATL-146e can ameliorate GVHD in allogeneic mouse models [13,14]. However, the 71 
action of A2A activation in humanised mouse models or HSCT patients remains to be 72 
explored. 73 
Allogeneic mouse models are often used to investigate potential therapeutics for GVHD, yet 74 
therapies investigated in these models often do not translate to the clinic. This lack of 75 
translation is possibly due to species differences. In an attempt to address this, preclinical 76 
“humanised” mouse models have been developed [15]. A commonly used humanised mouse 77 
model involves the intraperitoneal (i.p.) or intravenous (i.v.) injection of human peripheral 78 
blood mononuclear cells (hPBMCs) into immunodeficient non-obese diabetic severe-79 
combined immunodeficiency-IL-2 receptor γnull (NSG) mice. Due to defective T and B cells, 80 
and a lack of natural killer (NK) cells, these mice readily engraft hPBMCs [16], and 81 
subsequently develop GVHD due to the ability of human T cells to recognise the major 82 
histocompatibility complex (MHC) I and II of NSG mice [17]. Previous studies have shown 83 
that i.p. or i.v. injection of hPBMCs into these mice results in similar splenic engraftment of 84 
human leukocytes [17] and progression of clinical GVHD [18]. 85 
Using the A2A agonist CGS 21680 [19], this study aimed to investigate the effect of A2A 86 
activation on GVHD development in a humanised mouse model. CGS 21680 did not impact 87 
clinical score or survival of mice. However, CGS 21680 reduced leukocyte infiltration into 88 
livers, and reduced serum hTNF-α concentrations indicative of reduced GVHD severity. 89 
Conversely, CGS 21680 worsened weight loss, reduced Treg cell frequency and increased 90 
serum hIL-6 concentrations indicating worsened GVHD. Notably, CGS 21680 also prevented 91 
weight gain in NSG mice not engrafted with hPBMCs. This suggests that appetite or 92 
metabolism may be negatively impacted by CGS 21680. Therefore, the adverse impact on 93 
weight, Treg cells and IL-6 caused by CGS 21680 may confound the potential benefits of A2A 94 
activation in reducing GVHD in HSCT recipients. 95 
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 96 
MATERIALS AND METHODS 97 
Humanised mouse model of GVHD 98 
Experiments involving human blood and mice were approved by the respective Human and 99 
Animal Ethics Committees of the University of Wollongong (Wollongong, Australia). A 100 
humanised mouse model of GVHD was used as described [20]. Briefly, female NSG mice 101 
aged 6-8 weeks (Australian BioResources, Moss Vale, Australia) were injected i.p. daily 102 
(days -2 to day 11) with saline/0.2% DMSO (Sigma-Aldrich, St Louis, MO, USA) (vehicle) 103 
or vehicle containing CGS 21680 (Tocris Bioscience, Bristol, UK) (0.1 mg/kg). This 104 
injection schedule was based on that previously used for an A2A agonist in an allogeneic 105 
mouse model of GVHD [13]. hPBMCs, isolated by density centrifugation using Ficoll-Paque 106 
PLUS (GE Healthcare; Uppsala, Sweden) and resuspended in Dulbecco’s phosphate-buffer 107 
saline (ThermoFisher, Waltham, MA, USA), were injected i.p. (day 0) (10 x 106 108 
hPBMCs/mouse). At 3 weeks post-hPBMC injection, mice were checked for engraftment by 109 
immunophenotyping of tail vein blood. Mice were monitored for signs of GVHD using a 110 
scoring system, giving a total clinical score out of 10, as described [21]. Mice were 111 
euthanized at 10 weeks post-injection of hPBMCs, or earlier if exhibiting a clinical score of ≥ 112 
8 or a weight loss of ≥ 10%, according to the approved animal ethics protocol.  113 
Immunophenotyping by flow cytometry 114 
Tail vein blood (week 3) and spleen cells (end-point) were obtained from mice and lysed with 115 
ammonium chloride potassium buffer and immunophenotyped as described [21] using the 116 
antibodies listed in Table 1. Data was collected using a BD Fortessa-X20 Flow Cytometer 117 
(using band pass filters 450/50 for BV421, 710/50 for BV711, 525/50 for FITC, 586/15 for 118 
PE, 695/40 for PerCP-Cy5.5, 780/60 for PE-Cy7 and 670/30 for APC). The relative 119 
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percentages of cells were analysed using FlowJo software v8.7.1 (TreeStar Inc.; Ashland, 120 
OR, USA).  121 
Histological analysis 122 
Formalin-fixed tissue sections (5 μm) were stained with haematoxylin and eosin (POCD; 123 
Artarmon, Australia), with histology assessed using FIJI Is Just ImageJ (FIJI) [22] as 124 
described [23,24]. 125 
Cytokine analysis by a flow cytometric multiplex assay 126 
Serum was obtained from mice at end-point as described [21] and cytokine concentrations 127 
were measured using a Th1 LEGENDPlex kit (BioLegend, San Diego, CA, USA) as per the 128 
manufacturer’s instructions. 129 
In vitro T cell activation assay 130 
Freshly isolated hPBMCs (1 x 106 cells/mL) were incubated for 24 h at 37°C 95% air/5% 131 
CO2 in RPMI-1640 medium containing 2 mM L-glutamine, 1% non-essential amino acids, 55 132 
μM mercaptoethanol, 100 U/ml penicillin and 100 μg/ml streptomycin (all Thermo Fisher 133 
Scientific), 10% FBS (Bovogen, East Keller, Australia), 50 ng/ml phorbol 12-myristate 13-134 
acetate (PMA) (Sigma-Aldrich) and 1 μg/ml ionomycin (Sigma-Aldrich) in the presence or 135 
absence of 1 μM CGS 21680. Cells were then centrifuged (300 g for 5 min) and washed once 136 
with PBS (300 g for 5 min) and immunophenotyped as above. Data were collected using an 137 
LSRFortessa X-20 flow cytometer (band-pass filter 450/50 for BV421, 515/20 for FITC, 138 
586/25 for PE, and 780/30 for Zombie NIR (BioLegend)) and FACSDiva software version 139 
8.0. The relative percentages of Treg cells at 24 h were determined using FlowJo software 140 
v8.7.1 141 
 142 
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Statistical Analysis 143 
Data is given as mean ± standard error of the mean (SEM). Statistical differences were 144 
calculated using Student’s t-test for single comparisons or one-way analysis of variance 145 
(ANOVA) with Tukey’s post-hoc test for multiple comparisons. Weight and clinical score 146 
were analysed using a repeated measures two-way ANOVA. Survival (median survival time; 147 
MST) was compared using the log-rank (Mantel-Cox) test. Proportion of engraftment and 148 
mortality were compared using Fisher’s exact test. All statistical analyses and graphs were 149 
generated using GraphPad Prism 5 for PC (GraphPad Software, La Jolla, CA, USA). P < 0.05 150 
was considered significant for all tests. 151 
 152 
RESULTS 153 
CGS 21680 does not impact initial hPBMC engraftment in NSG mice 154 
NSG mice injected with hPBMCs and either control vehicle (n = 25) or the A2A agonist CGS 155 
21680 [19] (n = 25) daily (days -2 to 11) were monitored (from day 0) for up to 10 weeks. To 156 
determine whether A2A activation affected initial hPBMC engraftment, blood was collected 3 157 
weeks post-hPBMC injection and cells immunophenotyped by flow cytometry. Three mice 158 
from each group did not demonstrate human leukocytes (hCD45+mCD45-) in their blood at 3 159 
weeks (results not shown). In the remaining mice, human leukocytes were observed in the 160 
blood with frequency of these cells calculated as a percentage of total leukocytes 161 
[hCD45+mCD45-/(hCD45+mCD45- + hCD45-mCD45+)]. CGS 21680- and vehicle-injected 162 
mice demonstrated similar frequencies of human leukocytes (21.8 ± 2.8% and 22.8 ± 3.2%, 163 
respectively, P = 0.8221) (Fig 1a). The proportion of human leukocyte engraftment was the 164 
same in CGS 21680- and vehicle-injected mice (both 90%, P = 1.000). Likewise, the 165 
proportion of murine leukocytes was the same between CGS 21680- and vehicle-injected 166 
mice (72.3 ± 2.8% and 71.1 ± 3.4%, respectively, P = 0.8065; not shown). The majority of 167 
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the human leukocytes were T cells (95.7 ± 0.8% and 97.3 ± 0.6%, respectively, P = 0.1086) 168 
(Fig 1b), and a small frequency were non-B/T cells (3.8 ± 0.9 % and 3.4 ± 0.6%, respectively, 169 
P = 0.7502) (Fig 1c).  170 
CGS 21680 reduces human Treg cells in humanised NSG mice 171 
To determine if CGS 21680 impacted hPBMC engraftment at end-point, splenocytes from 172 
CGS 21680- (n = 20) and vehicle-injected mice (n = 20) were analysed by flow cytometry. 173 
Human leukocytes were absent in the spleens of the same three mice from each group that 174 
failed to show hPBMC engraftment at 3 weeks (results not shown). Frequencies of human 175 
leukocytes in mice engrafted at end-point were similar in CGS 21680- and vehicle-injected 176 
mice (70.5 ± 3.2% and 65.1 ± 6.0%, respectively, P = 0.4348) (Fig 1d). Likewise, the 177 
proportion of murine leukocytes was the same between CGS 21680- and vehicle-injected 178 
mice (26.2 ± 2.9% and 26.7 ± 4.3%, respectively, P = 0.9278; not shown). 179 
Similar to blood at 3 weeks post-hPBMC injection, the majority of engrafted human 180 
leukocytes in both groups of mice were T cells, which did not differ between CGS 21680- 181 
(93.4 ± 1.8%) and vehicle-injected mice (93.6 ± 1.5%) (P = 0.9546) (Fig 1e). Further analysis 182 
of human T cells demonstrated that CGS 21680- and vehicle-injected mice demonstrated 183 
similar engraftment of hCD4+ T cells (67.2 ± 3.0% and 58.3 ± 3.7%, respectively, P = 184 
0.0713) and hCD8+ T cells (18.0 ± 2.3% and 24.4 ± 3.3%, respectively, P = 0.1260). Both 185 
CGS 21680- and vehicle-injected mice demonstrated greater engraftment of hCD4+ than 186 
hCD8+ cells (P < 0.0001 and P < 0.0001, respectively) (Fig 1f).  187 
To investigate whether CGS 21680 affected CD39 and/or CD73 on human T cells, these 188 
ecto-nucleotidases on hCD4+ and hCD8+ T cell subsets from the spleens of mice were 189 
examined. CGS 21680-injected demonstrated a trend of increased hCD39+hCD73-hCD4+ T 190 
cells compared to vehicle-injected mice (15.6 ± 3.0% and 9.1 ± 2.0%, respectively, P = 191 
0.0796). Conversely, CGS 21680-injected mice demonstrated significantly reduced 192 
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frequencies of hCD39-hCD73+hCD4+ T cells (2.5 ± 0.7% and 8.9 ± 2.6, respectively, P = 193 
0.0227), and a reduced trend of hCD39+hCD73+hCD4+ T cells (1.3 ± 0.3% and 3.1 ± 1.1%, 194 
respectively, P = 0.1137) compared to vehicle-injected mice. However, CGS 21680- and 195 
vehicle-injected mice demonstrated similar frequencies of hCD39-hCD73-hCD4+ T cells 196 
(80.6 ± 3.0% and 78.8 ± 4.1%, respectively, P = 0.7358) (Fig 1g). CGS 21680- and vehicle-197 
injected mice demonstrated similar frequencies of hCD39+hCD73-hCD8+ T cells (40.6 ± 198 
5.9% and 39.7 ± 5.0%, respectively, P = 0.9036), hCD39-hCD73+hCD8+ T cells (3.0 ± 1.0% 199 
and 4.2 ± 1.2%, respectively, P = 0.4508), hCD39+hCD73+hCD8+ T cells (4.0 ± 1.1% and 7.3 200 
± 2.2%, respectively, P = 0.1877) and hCD39-hCD73-hCD8+ T cells (52.3 ± 4.7% and 51.4 ± 201 
5.9%, respectively, P = 0.9137) (Fig 1h).  202 
In allogeneic mouse models increased frequencies of iNKT and Treg cells correlates with 203 
reduced GVHD [4]. Therefore, the frequency of human iNKT cells 204 
(hCD45+hCD3+hCD19-hVα24-Jα18+) and human Treg cells 205 
(hCD45+hCD3+hCD4+hCD25+hCD127lo) in spleens from mice were examined. CGS 21680-206 
injected mice, compared to vehicle-injected mice, demonstrated a reduced trend of iNKT 207 
cells (2.7 ± 0.6% and 4.7 ± 1.1%, respectively, P = 0.1223) (Fig 3i) and significantly reduced 208 
Treg cells (0.4 ± 0.1% and 0.9 ± 0.2%, respectively, P = 0.0130) (Fig 1j).  209 
Our group has previously shown that at end-point the spleens of humanised mice do not 210 
contain human B cells [21]. Similarly, in the current study the remaining human leukocytes in 211 
the spleens of mice were negative for CD19. CGS 21680- and vehicle-injected mice 212 
demonstrated small but similar frequencies of CD3-CD19- cells present in both groups of 213 
mice (3.2 ± 0.8% and 4.7 ± 0.8%, respectively, P = 0.1783) (Fig 1k). To determine if human 214 
monocytes (hCD14+hCD83-) or DCs (hCD14-hCD83+) were present, the remaining non-B/T 215 
cell population (hCD45+hCD3-hCD19-) was analysed. CGS 21680- and vehicle-injected mice 216 
demonstrated similar but low frequencies of monocytes (0.4 ± 0.2% and 0.6 ± 0.2%, 217 
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respectively, P = 0.6127) (Fig 1l) and DCs (0.2 ± 0.1%, and 0.7 ± 0.3%, respectively, P = 218 
0.1160) (Fig 1m).  219 
The above data (Fig 1j) demonstrates that CGS 21680 significantly reduced Treg cells in 220 
humanised mice. To determine if CGS 21680 had a negative impact on Treg cells, hPBMCs 221 
were stimulated in vitro for 24 h with PMA and ionomycin in the absence or presence of 222 
CGS 21680, and the proportion of Treg cells determined by flow cytometry. CGS 21680 was 223 
used at 1 μM, a concentration with known efficacy in vitro [25,26]. As previously reported 224 
[27], stimulation with PMA and ionomycin increased the proportion of Treg cells in hPBMC 225 
cultures (Fig 1n), however  the proportion were not significantly up-regulated in the absence 226 
(14.9 ± 7.4%) or presence (11.3 ± 6.3%) of CGS 21680 (P = 0.7294). This data indicates that 227 
CGS 21680 does not have a negative impact on Treg cell differentiation. 228 
CGS 21680 worsens weight loss in humanised NSG mice 229 
To investigate whether A2A activation impacts GVHD, the above mice were monitored for 230 
weight loss and other signs of GVHD for up to 10 weeks. One engrafted vehicle-injected 231 
mouse died unexpectedly overnight from unknown causes and was excluded from the 232 
following analyses. In those mice which had engrafted hPBMCs, CGS 21680-injected mice 233 
(n = 22) demonstrated significantly greater weight loss over the 10 weeks than vehicle-234 
injected mice (n = 21) (P = 0.0020) (Fig 2a). However, both CGS 21680- and vehicle-235 
injected mice demonstrated signs of GVHD (classified as a score clinical score > 3) from 35 236 
days onwards with similar scores (P = 0.8008) (Fig 2b), survival (MST; 41 days, and 43 237 
days, respectively, P = 0.6730) and mortality rates (90% and 82%, respectively, P = 0.6640) 238 
(Fig 2c) over the 10 weeks. 239 
CGS 21680 prevents healthy weight gain in NSG mice not engrafted with hPBMCs 240 
As noted above, three NSG mice from each treatment group did not engraft hPBMCs. 241 
Nevertheless, these mice were also monitored for weight loss and signs of GVHD for 10 242 
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weeks as per the engrafted mice above. CGS 21680-injected mice gained significantly less 243 
weight over the 10 weeks compared to vehicle-injected mice (P = 0.0029) (Fig 2d). Both 244 
CGS 21680- and vehicle-injected mice demonstrated similar but minimal clinical signs of 245 
GVHD over the 10 weeks (mean clinical scores of 0.4 ± 0.2 and 0.3 ± 0.2) (P = 0.4557) (Fig 246 
2e) consistent with the lack of hPBMC engraftment. Moreover, all CGS 21680- and vehicle-247 
injected mice not engrafted with hPBMCs survived the entire 10 weeks (Fig 2f). 248 
CGS 21680 reduces liver infiltrates in humanised NSG mice 249 
Tissues from mice which had engrafted hPBMCs (n = 20 per group) were examined by 250 
histology. Livers from CGS 21680-injected mice demonstrated reduced leukocyte infiltration 251 
(1548.0 ± 121.4, n = 9) compared to vehicle-injected mice (2054.0 ± 13.3, n = 9) (P = 252 
0.0059) but all mice demonstrated similar structural damage (Fig 3a, b). CGS 21680- and 253 
vehicle-injected mice demonstrated similar histology and leukocyte infiltration into small 254 
intestines (841.6 ± 37.4, n = 9 and 821.1 ± 107.7, n = 9, P = 0.8530) and skin (1128.0 ± 97.3, 255 
n = 9 and 1139 ± 196.1, n = 9, P = 0.9593) (Fig 3a). CGS 21680- and vehicle-injected mice 256 
also demonstrated similar epidermal thickening of the skin (88.0 ± 6.9 μm, n = 14 and 82.2 ± 257 
5.5 μm, n = 14, P = 0.5235) (Fig 3c). 258 
CGS 21680 increases serum hIL-6 but reduces hTNF-α in humanised NSG mice 259 
The pro-inflammatory cytokine storm that preludes immune cell infiltration and 260 
inflammatory damage of target organs is an important stage of GVHD pathogenesis [28]. 261 
Therefore, to determine if A2A activation impacts human cytokines, a multiplex assay was 262 
used to analyse concentrations of serum hIL-2, hIL-6, hIL-10, hTNF-α, and hIFN-γ from 263 
CGS 21680-injected mice (n = 15) and vehicle-injected (n = 18).  264 
Mean serum hIL-2 concentrations were 83% lower in CGS 21680-injected mice compared to 265 
vehicle-injected but this was not significantly different (7.0 ± 1.2 pg/mL and 41.8 ± 28.1 266 
pg/mL, respectively; P = 0.2379) (Fig 3a). However, CGS 21680-injected demonstrated a 267 
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significant four-fold increase in hIL-6 concentrations compared to vehicle-injected mice 268 
(141.0 ± 79.3 pg/mL and 35.4 ± 27.8 pg/mL, respectively; P < 0.0001). There was an 89% 269 
decrease in serum hIL-10 in CGS 21680-injected mice compared to vehicle-injected mice, 270 
but this did not reach statistical significance (18.9 ± 4.8 pg/mL and 170.0 ± 93.1 pg/mL, 271 
respectively; P = 0.0800) (Fig 4c) and a significant 75% decrease in hTNF-α concentrations 272 
(18.9 ± 4.8 pg/mL, and 77.0 ± 40.1 pg/mL, respectively; P = 0.0411) (Fig 4d). hIFN-γ 273 
concentrations in both treatment groups exceeded the highest standard (>10,000 pg/mL) (data 274 
not shown) and could not be compared. 275 
 276 
DISCUSSION 277 
Previous studies have shown that the CD73/A2A pathway reduces disease severity in 278 
allogeneic mouse models of GVHD [11-14]. However, the effect of A2A activation in 279 
humanised mouse models or in HSCT patients has not been reported. Using a humanised 280 
NSG mouse model of GVHD, the current study demonstrated that the A2A agonist CGS 281 
21680 had opposing roles in disease development. CGS 21680 did not affect clinical score or 282 
mortality in humanised mice but reduced GVHD severity, as indicated by decreased 283 
leukocyte infiltration into the liver and serum hTNF-α in these mice. Unexpectedly, CGS 284 
21680 increased weight loss and serum hIL-6, and reduced the frequency of Tregs, indicating 285 
this A2A agonist worsens these disease parameters in this humanised mouse model of GVHD.  286 
CGS 21680 reduced leukocyte infiltration into the liver and serum hTNF-α indicating GVHD 287 
is reduced, at least in part, in humanised mice. This indicates that A2A activation has 288 
beneficial roles in this model. This finding parallels similar observations in allogeneic mouse 289 
models of GVHD where the A2A agonist ATL-146e reduces histological damage, leukocyte 290 
infiltration in livers and serum TNF-α [13,14]. Conversely, pharmacological blockade or 291 
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genetic deficiency of CD73, which limits extracellular adenosine [29], worsens liver 292 
histology in allogeneic mouse models of GVHD [11,12]. Of note, in allogeneic and 293 
humanised mouse models of GVHD, increased TNF-α levels correspond with disease 294 
severity [30,31] and blockade of this cytokine impairs GVHD in both of these models 295 
[17,32]. Thus, collectively these studies suggest a crucial role for TNF-α in GVHD, and that 296 
activation of A2A can limit this in both allogeneic and humanised mouse models of this 297 
disease. 298 
Contrary to above, the current study suggests that CGS 21680 worsens aspects of GVHD in 299 
humanised mice as evidenced through increased weight loss. This indicates that A2A 300 
activation also has adverse roles in this model. Weight loss is a common indicator of disease 301 
severity in mouse models of GVHD [33]. The dose of CGS 21680 (0.1 mg/kg) used in this 302 
study is sufficient to prevent disease in mouse models of acute lung inflammation [34], 303 
pleurisy [35] and collagen-induced arthritis [36]. These studies reported no effect of CGS 304 
21680 on weight, suggesting weight loss in CGS 21680-injected humanised mice is due in 305 
part to worsened GVHD. Supporting this, serum IL-6 was also increased in humanised mice. 306 
Although, hIL-6 has not been previously detected in the serum of humanised mice [31,37,38], 307 
and its role in humanised mouse models of GVHD remains to be elucidated, IL-6 is 308 
implicated in GVHD progression in allogeneic mouse models [39,40]. In the current study, 309 
the increased serum hIL-6 concentrations were unexpected, as previously ATL-146e reduced 310 
serum IL-6 concentrations in allogeneic mouse models of GVHD [13,14]. Moreover, CGS 311 
21680 reduces IL-6 release from ex vivo anti-CD3/anti-CD28-stimulated murine effector T 312 
cells [41]. Conversely, increased serum IL-6 concentrations correlate to disease severity as a 313 
result of A2A blockade in an allogeneic mouse model of GVHD [12]. The reason for 314 
increased serum hIL-6 concentrations in CGS 21680-injected humanised mice remains 315 
unknown but supports the concept that A2A activation has adverse roles in this model. 316 
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In the current study, the frequency of Treg cells was also reduced. This further supports the 317 
concept that A2A activation has detrimental roles in humanised mice. Treg cells inversely 318 
correlate to GVHD progression in allogeneic [42] and humanised mouse models [43], as well 319 
as in HSCT recipients [44,45]. The observed reduction in Treg cells was contrary to 320 
expectations, as in allogeneic mouse models ATL-146e increases Treg cells to ameliorate 321 
disease development [13,14]. The mechanism by which CGS 21680 decreases Treg cells in 322 
the current study remains to be established. However, CGS 21680 reduced, albeit not 323 
significantly, serum hIL-2 and hIL-10 in humanised mice. These cytokines are important for 324 
maintenance of Treg cells in humanised mice [38,46]. Thus, a decrease in one or both of 325 
these cytokines may have contributed to the lower frequency of Treg cells in CGS 21680-326 
injected mice. Alternatively, although not mutually exclusive to the above, IL-6 with IL-1β 327 
reduces Treg cell numbers through their conversion to Th1 and/or Th17 cells [47]. Thus, the 328 
increased IL-6 in CGS 21680-injected mice may have contributed to the reduction in Treg 329 
cells. However, it should be noted that the amount of hIL-1β mRNA [21] and serum hIL-1β 330 
[38] in humanised mice is negligible, thereby potentially limiting the ability of hIL-6 to 331 
convert Treg cells to Th cells in this model. 332 
One other point of note is that a high, but similar, proportion of human CD39+CD73-CD8+ T 333 
cells were observed at end-point in both CGS 21680- and vehicle-injected humanised mice. 334 
These cells may represent exhausted CD8+ T cells, as recently described in a murine model of 335 
viral infection [48]. If so, this would be consistent with persistent antigen experience and 336 
activation of human CD8+ T cells [49] in humanised mice. Which provides indirect evidence 337 
these CD8+ T cells (along with CD4+ T cells) mediate GVHD in this model, as demonstrated 338 
by others [17,50,51]. 339 
The current study also demonstrated that CGS 21680 prevented healthy weight gain in NSG 340 
mice not engrafted with hPBMCs. This suggests that this A2A agonist may be suppressing 341 
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appetite or metabolism in these mice, which may also be contributing to the increased weight 342 
loss in hPBMC-engrafted NSG mice in addition to GVHD. In rats, CGS 21680, at the same 343 
dose used in the current study, is sufficient to prevent weight gain by reducing food intake 344 
[52,53]. Moreover, CGS 21680 at this dose increases energy expenditure in mice to prevent 345 
diet-induced obesity [54] and causes hypothermia [55]. The reasons for the different effects 346 
of CGS 21680 on mouse weight in these and the current studies compared to those discussed 347 
above [34-36]  remains unknown, but may reflect strain differences. CGS 21680-mediated 348 
effects on metabolism and weight were observed in C57BL/6 mice [54,55] and NSG mice 349 
(this study), whilst CGS 21680 was reported to have no such effects in CD1, Swiss and 350 
DBA/1 mice [34-36]. Finally, it should be noted that IL-6 can potentially impact mouse body 351 
weight, as genetic deficiency of IL-6 promotes obesity [56]. Thus, the increased weight loss 352 
observed in CGS 21680-injected humanised mice may be mediated via an IL-6-dependent 353 
mechanism. Regardless, given the confounding effects of CGS 21680 on GVHD in 354 
humanised NSG mice, as well as the effect of this compound on weight loss in non-engrafted 355 
NSG mice and other mouse strains, the use of CGS 21680 to activate A2A in allogeneic 356 
mouse models of GVHD should be avoided. 357 
In summary, the A2A agonist CGS 21680 has opposing effects in a humanised mouse model 358 
of GVHD. Moreover, CGS 21680 can prevent weight gain in healthy NSG mice. Therefore, 359 
the therapeutic efficacy of A2A activation with CGS 21680 in HSCT recipients may be 360 
limited by adverse effects on weight, decreased Treg cell frequency and increased IL-6 361 
production. 362 
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 570 
FIGURE LEGENDS 571 
Figure 1. CGS 21680 reduces human T regulatory cells in humanised NSG mice 572 
(a-m) NSG mice were injected daily with either saline/0.2% DMSO (vehicle) or vehicle 573 
containing CGS 21680 (0.1 mg/kg) (day -2 to day 11), and with 10 x 106 hPBMCs (day 0).  574 
The percentages of human (h) leukocytes and subsets in (a-c) blood at 3 weeks post-hPBMC 575 
injection and (d-m) spleens at end-point were determined by flow cytometry. (a, d) Human 576 
leukocytes (hCD45+mCD45-) are expressed as a percentage of total mCD45+ and hCD45+ 577 
leukocytes. Three mice from each group did not engraft hCD45+ leukocytes (not shown). (b, 578 
e) hCD3+hCD19- cells and (c, k) hCD3-hCD19- cells are expressed as a percentage of total 579 
hCD45+ leukocytes. (f) hCD4+ and hCD8+ T cell subsets are expressed as a percentage of 580 
total hCD3+ leukocytes. ** P < 0.005, *** P < 0.0001 compared to hCD8+ T cells. (g-h) 581 
hCD39 and hCD73 expression was analysed on (g) hCD4+ and (h) hCD8+ T cell subsets. * P 582 
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< 0.05 compared to vehicle. (i) Invariant natural killer T (iNKT) cells 583 
(hCD45+hCD3+hCD19-hVα24-Jα18+) are expressed as a percentage of hCD3+hCD19- T cells 584 
and (j) T regulatory (Treg) cells (hCD45+hCD3+hCD4+hCD25+hCD127lo) are expressed as a 585 
percentage of hCD3+hCD4+ T cells. * P < 0.05 compared to vehicle. (l) Monocytes 586 
(hCD14+hCD83-) and (m) dendritic cells (DCs) (hCD14-hCD83+) are expressed as a 587 
percentage of hCD45+hCD3-hCD19- cells. (n) Freshly isolated hPBMCs were incubated for 588 
24 h in the absence (No Stim) or presence (Stim) of 50 ng/ml PMA and 1 μg/ml ionomycin, 589 
in the absence or presence of 1 μM CGS 21680 (CGS), and the proportion of Tregs 590 
(hCD4+hCD25+hCD127loZombie NIR-) as a percentage of hCD4+Zombie NIR- T cells 591 
determined by flow cytometry. (a-m) Data represents group means ± SEM (vehicle n = 20-592 
22, CGS 21680 n = 20-22); symbols represent individual mice. (n) Data represents group 593 
means ± SEM (n = 3); symbols represent individual human donors. 594 
Figure 2. CGS 21680 worsens weight loss in NSG and humanised NSG mice 595 
(a-f) NSG mice were injected daily with either saline/0.2% DMSO (vehicle) or vehicle 596 
containing CGS 21680 (0.1 mg/kg) (day -2 to day 11), and with 10 x 106 hPBMCs (day 0). 597 
NSG mice engrafted with hPBMCs were monitored for (a) weight loss, (b) clinical score, and 598 
(c) survival over 10 weeks. Data represents (a, b) group means ± SEM or (c) percent survival 599 
(vehicle n = 22, CGS 21680 n = 21). ** P < 0.005 compared to vehicle-injected mice. (d – f) 600 
Mice which were not engrafted with hCD45+ leukocytes at 3 weeks (blood) and at 10 weeks 601 
(spleen) (results not shown) were monitored for (d) weight loss, (e) clinical score, and (f) 602 
survival. Data represents (d, e) group means ± SEM or (f) percent survival (vehicle n = 3, 603 
CGS 21680 n = 3). ** P < 0.005 compared to vehicle-injected mice. 604 
Figure 3. CGS 21680 reduces liver infiltrates in humanised NSG mice 605 
(a-c) NSG mice were injected daily with either saline/0.2% DMSO (vehicle) or vehicle 606 
containing CGS 21680 (0.1 mg/kg) (day -2 to day 11), and with 10 x 106 hPBMCs (day 0). 607 
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Tissue sections (liver, small intestine, and skin) from hPBMC-engrafted mice were stained 608 
with haematoxylin and eosin. Images were captured by microscopy with each image 609 
representative of twenty mice per group; bars represent 100 μm. (b) Leukocyte infiltration 610 
(vehicle n = 9, CGS 21680 n = 9) and (c) epidermal thickness (vehicle n = 14, CGS 21680 n 611 
= 14) were quantified using FIJI Is Just ImageJ (FIJI). Data represents group means ± SEM; 612 
** P < 0.005 compared to vehicle-injected mice. 613 
Figure 4. CGS 21680 impacts serum cytokines in humanised NSG mice 614 
(a-d) NSG mice were injected daily with either saline/0.2% DMSO (vehicle) or vehicle 615 
containing CGS 21680 (0.1 mg/kg) (day -2 to day 11), and with 10 x 106 hPBMCs (day 0).  616 
Concentrations of serum human (a) interleukin (IL)-2, (b) IL-6, (c) IL-10, and (d) tumour 617 
necrosis factor (TNF)-α from hPBMC-engrafted mice were analysed by a flow cytometric 618 
multiplex assay. Data represents group means ± SEM (vehicle n = 18, CGS 21680 n = 15); * 619 
P < 0.05, *** P < 0.0001 compared to vehicle-injected mice. 620 
 621 
TABLE 622 
Table 1. Monoclonal antibodies used for flow cytometry. 623 
Target Fluorochrome Clone* 
CD3 BV711 UCHT1 
CD4 PerCP-Cy5.5 L200 
CD8 FITC RPA-T8 
CD14 BV421 MϕP9 
CD19 APC HIB19 
CD25 PE M-A251 
CD39 APC TU66 
CD45 FITC HI30 
CD45 PerCP-Cy5.5 30-F11 
CD73 PE-Cy7 AD2 
CD83 PE HB15e 
CD127 BV421 HIL-7R-M21 
Vα24-Jα14 TCR PE-Cy7 6B11 
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*All antibodies were mouse anti-human except clone 30-F11 (rat anti-mouse); all antibodies were 624 
from BD Biosciences except clone 6B11 (BioLegend). Abbreviations: APC, allophycocyanin; BV, 625 
brilliant violet; Cy, cyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP, peridinin 626 
chlorophyll protein; TCR, T cell receptor. 627 
628 
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